|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with other banks | ||||||||||||||||||||
| Cash and Cash Equivalents | ||||||||||||||||||||
| FRB and FHLB stock | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| AFS, at estimated fair value | ||||||||||||||||||||
| HTM, at amortized cost | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Less: ACL - loans | ||||||||||||||||||||
| Loans, Net | ||||||||||||||||||||
| Net premises and equipment | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Goodwill and net intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total Deposits | ||||||||||||||||||||
| Federal funds purchased | ||||||||||||||||||||
| FHLB advances | ||||||||||||||||||||
| Senior debt and subordinated debt | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Total Borrowings | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Preferred stock, no par value, 10,000,000 shares authorized; Series A, 200,000 shares issued as of June 30, 2026 and December 31, 2025, liquidation preference of $1,000 per share | ||||||||||||||||||||
| Common stock, $2.50 par value, 600,000,000 shares authorized, 248,210,978 shares issued as of June 30, 2026 and 247,130,331 shares issued as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost, 56,750,100 shares as of June 30, 2026 and 67,235,204 shares as of December 31, 2025 | ||||||||||||||||||||
| Total Shareholders' Equity | ||||||||||||||||||||
| Total Liabilities and Shareholders' Equity | ||||||||||||||||||||
Loading...
